Efficacy and Safety of Trastuzumab as a Single Agent in First-Line

trastuzumab  A study of more than 4000 patients, published in 2014, showed that adding trastuzumab to chemotherapy led to a 37% relative improvement in Trastuzumab deruxtecan Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal

trastuzumab A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 Trastuzumab emtansine is a HER2-targeted, microtubule-stabilizing antibody-drug conjugate with about 3 chemotherapy molecules per antibody

Trastuzumab side effects · heart problems; · nausea, diarrhea, weight loss; · headache; · trouble sleeping, feeling tired; · low blood cell Self-Care Tips: · Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise · Trastuzumab causes little nausea · You may